Literature DB >> 23250126

Prevalence of lifestyle risk factors in myotonic dystrophy type 1.

Cynthia Gagnon1, Maud-Christine Chouinard, Luc Laberge, Diane Brisson, Daniel Gaudet, Mélissa Lavoie, Nadine Leclerc, Jean Mathieu.   

Abstract

BACKGROUND: The prevalence of unhealthy lifestyle habits such as smoking has seldom been described in neuromuscular disorders, including myotonic dystrophy type 1 (DM1). However, it is essential to document the unhealthy lifestyle habits as they can exacerbate existing impairments and disabilities. The objectives are: 1) To determine the prevalence of risk factors among individuals with DM1; 2) To compare the prevalence among classic and mild phenotypes.
METHOD: A survey was done on a sample of two-hundred (200) patients with DM1 as part of a larger study. Lifestyle risk factors included being overweight or obese, tobacco smoking, illicit drug use, excessive alcohol consumption and physical inactivity. A registered nurse administered the validated public health survey. Categorization of risk factors were based on national standards and compared with provincial and regional prevalences.
RESULTS: 50% of DM1 patients were overweight or obese, 23.6% were regular smokers, and 76% were physically inactive. Except for overweight and obesity, significant differences were observed between patients with classic and mild phenotypes for all the other lifestyle risk factors: those with the classic phenotype being more often regular smokers, consuming more often illicit drugs and being less physically active.
CONCLUSIONS: The results of this study will provide guidance for the development of better adapted and focussed health promotion interventions in the future.

Entities:  

Mesh:

Year:  2013        PMID: 23250126     DOI: 10.1017/s0317167100012932

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  7 in total

1.  Noninvasive Home Mechanical Ventilation in Adult Myotonic Dystrophy Type 1: A Systematic Review.

Authors:  Bettine A H Vosse; Charlotte Seijger; Nicolle Cobben; Baziel van Engelen; Sander M J van Kuijk; Catharina Faber; Peter Wijkstra
Journal:  Respiration       Date:  2021-05-07       Impact factor: 3.580

2.  Overweight Is an Independent Risk Factor for Reduced Lung Volumes in Myotonic Dystrophy Type 1.

Authors:  Charlotte G W Seijger; Gea Drost; Joram M Posma; Baziel G M van Engelen; Yvonne F Heijdra
Journal:  PLoS One       Date:  2016-03-25       Impact factor: 3.240

3.  Elevated plasma levels of cardiac troponin-I predict left ventricular systolic dysfunction in patients with myotonic dystrophy type 1: A multicentre cohort follow-up study.

Authors:  Mark J Hamilton; Yvonne Robb; Sarah Cumming; Helen Gregory; Alexis Duncan; Monika Rahman; Anne McKeown; Catherine McWilliam; John Dean; Alison Wilcox; Maria E Farrugia; Anneli Cooper; Josephine McGhie; Berit Adam; Richard Petty; Cheryl Longman; Iain Findlay; Alan Japp; Darren G Monckton; Martin A Denvir
Journal:  PLoS One       Date:  2017-03-21       Impact factor: 3.240

4.  Metabolic impairments in patients with myotonic dystrophy type 2.

Authors:  Milorad Vujnic; Stojan Peric; Zeljka Calic; Natasa Benovic; Tanja Nisic; Jovan Pesovic; Dusanka Savic-Pavicevic; Vidosava Rakocevic-Stojanovic
Journal:  Acta Myol       Date:  2018-12-01

Review 5.  Insulin Signaling as a Key Moderator in Myotonic Dystrophy Type 1.

Authors:  Sylvia Nieuwenhuis; Kees Okkersen; Joanna Widomska; Paul Blom; Peter A C 't Hoen; Baziel van Engelen; Jeffrey C Glennon
Journal:  Front Neurol       Date:  2019-11-26       Impact factor: 4.003

6.  Cardiac Involvement and Arrhythmias Associated with Myotonic Dystrophy.

Authors:  Daniel McBride; Amrish Deshmukh; Supriya Shore; Melissa A Elafros; Jackson J Liang
Journal:  Rev Cardiovasc Med       Date:  2022-04-02       Impact factor: 4.430

7.  Nationwide patient registry for GNE myopathy in Japan.

Authors:  Madoka Mori-Yoshimura; Yukiko K Hayashi; Naohiro Yonemoto; Harumasa Nakamura; Miho Murata; Shin'ichi Takeda; Ichizo Nishino; En Kimura
Journal:  Orphanet J Rare Dis       Date:  2014-10-11       Impact factor: 4.123

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.